NCT04466215已完成2 期
Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Craving to Drink
研究概览
简要总结
The hypotheses under test are that subjects with alcohol use disorder (AUD) of moderate or greater severity treated with CORT118335 will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under naturalistic conditions, than those treated with placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female volunteers, 18-75 years of age.
- •Meets DSM-5 criteria for current alcohol use disorder of moderate or greater severity (AUD-MS).
- •Subjects will not be seeking treatment because the medication studies are not treatment trials, and to avoid exposing treatment-seekers to alcohol cues.
- •Subjects must be abstinent a minimum of 3 days (but not more than 7 days) prior to the human lab session.
- •In acceptable health in the judgment of the study physician, based on interview, medical history, physical exam, ECG, routine urine and blood chemistry.
- •Subjects with a history of depression, who have been on a stable dose of anti-depressant medication for at least 3 months, and do not meet current DSM-5 criteria for depression or anxiety.
- •All subjects must agree to use double barrier birth control for the study duration and one month thereafter i.e., males must use condoms and females must use spermicide and/or a non hormonal barrier method, and their opposite sex partner must likewise use an effective non hormonal form of contraception.
- •Able to provide informed consent and understand questionnaires and study procedures in English.
- •Willing to comply with the provisions of the protocol and take daily oral medication
排除标准
- •Medical conditions that could be aggravated by glucocorticoid and/or mineralocorticoid antagonism.
- •Clinically significant findings on physical exam, ECG, urine or blood tests that may increase risk.
- •CYP2C19 inhibitors
- •Substrates metabolized primarily by CYP3A, CYP2C9, and CYP2C8 with narrow therapeutic index
- •BCRP and UGT1A1 substrates
- •Meets DSM-5 criteria for a current major psychiatric disorder, including mood, anxiety or substance use disorders, other than alcohol, nicotine, or mild cannabis use disorders.
- •Pregnant or lactating.
- •Treatment within the month prior to screening with (1) an investigational drug, (2) drugs which may negatively interact with study medications, or (3) drugs that may influence study outcomes (e.g., disulfiram [Antabuse], naltrexone [ReVia], acamprosate [Campral], or anticonvulsants.
- •Chronic systemic steroid use
- •Using drugs that are strong inhibitors and inducers of CYP2C
- •No fixed domicile and/or no availability by home or mobile telephone.
研究组 & 干预措施
Miricorilant
Active Comparator
900 mg (6 x 150 mg) tablets daily taken orally for two weeks
干预措施: Miricorilant (Drug)
Placebo
Placebo Comparator
Six placebo tablets taken orally for two weeks
干预措施: Placebo oral tablet (Drug)
结局指标
主要结局
Craving to Drink
时间窗: 1 hour on the last day of dosing (Day 14)
Total Visual Analog Scale (VAS) scores of craving severity in response to in vivo alcohol cues. Higher scores indicate greater craving severity with a minimum score of 0 and a maximum score of 80.
次要结局
- Drinking(11 days (Treatment effects on drinking were assessed during the 11 days of ad libitum drinking))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Medication Development in Alcoholism: Suvorexant Versus PlaceboAlcohol Use Disorder (AUD)NCT04229095The Scripps Research Institute26
已完成
2 期
Medication Development in Alcoholism: Apremilast Versus PlaceboAlcohol Use DisorderNCT03175549The Scripps Research Institute51
已完成
2 期
Medication Development in Alcoholism: Acamprosate Versus NaltrexoneAlcoholismNCT00656630The Scripps Research Institute68
已完成
4 期
Behavioral/Drug Therapy for Alcohol-Nicotine Dependence (Naltrexone/Nicotine Patch)SmokingAlcoholismNCT00000447The University of Texas Health Science Center, Houston200
已完成
3 期
Effects of Omegas 3 and 6 on Alcohol DependenceAlcohol DependenceNCT01211769Federal University of São Paulo80